Kodiak Sciences Inc.
KOD
주식 순위
#3226
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical... Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
주가
$87.38
마지막 동기화: 2026-10-21
시가총액
$5.49B
변동 (1일)
-6.01%
변동 (1년)
384.10%
국가
US
거래 Kodiak Sciences Inc. (KOD)
카테고리
Healthcare
Kodiak Sciences Inc. (KOD)의 주가 이력
최고 종가: $92.12 (2026-10-01 기준)
최저 종가: $1.97 (2018-10-01 기준)
최저 종가: $1.97 (2018-10-01 기준)
Kodiak Sciences Inc.의 주가 이력 (2018 ~ 2026)
연간 주가 성과
| 연도 | 성과 |
|---|---|
| 2026 (TTM) | 40.19% |
| 2025 | 191.32% |
| 2024 | 200.90% |
| 2023 | -58.27% |
| 2022 | -59.80% |
| 2021 | -36.18% |
| 2020 | 106.84% |
| 2019 | 776.39% |
| 2018 | 0.00% |
유사 기업 또는 경쟁사의 주가
| 회사 | 주가 | 변동률 1년% | 국가 |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.24 | -4.19% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
